Serum antibody levels after immunization with trivalent oral poliovirus vaccine

Insights

Seventy-seven infants received three doses of oral poliovirus vaccine. Antibody titres to all three poliovirus types were achieved in 77% of children, with further studies recommended.

Area of Science:

  • Pediatrics
  • Immunology
  • Vaccinology

Background:

  • The oral poliovirus vaccine (OPV) is crucial for polio eradication.
  • Assessing vaccine immunogenicity in infants is vital for public health strategies.

Purpose of the Study:

  • To evaluate antibody titres to polioviruses in infants after trivalent oral poliovirus vaccine (tOPV) administration.
  • To identify the prevalence of seroconversion and potential vaccine failure in a cohort of young children.

Main Methods:

  • Seventy-seven infants aged 3-9 months received three doses of tOPV.
  • Neutralizing antibody titres were measured to assess immune response to all three poliovirus types.

Main Results:

  • 59 out of 77 (77%) infants achieved protective antibody titres (≥1:10) against all three poliovirus types.
  • 18 infants (23%) lacked demonstrable antibodies to one or more poliovirus types, most commonly types 1 and 3.

Conclusions:

  • While 77% seroconversion is substantial, a significant proportion of infants did not achieve adequate antibody titres after three OPV doses.
  • Further research into additional vaccine doses and their impact on serum antibody levels is recommended to address vaccination failures.